

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 4

Complete If Known

Application Number	10/033,145
Filing Date	November 5, 2001
First Named Inventor	Roberts, Bruce L.
Group Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	GA0201C

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
PS	1	US-5,695,937	12-09-1997	Kinzler et al.	
	2	US-			
	3	US-			
	4	US-			
	5	US-			
	6	US-			
	7	US-			
	8	US-			
	9	US-			
	10	US-			
	11	US-			
	12	US-			
	13	US-			
	14	US-			
	15	US-			
	16	US-			
	17	US-			
	18	US-			
	19	US-			
	20	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
PS	21	EP 0363025	04-11-90	Hsrch Found/ Osaka Univ.		
	22	EP 0431541	12-06-91	Behringwerke		
	23	WO 91/08217	06-13-91	Regents-UCAL		
	24	WO 92/00387	09-01-92	Regents- UMICHIGAN		
	25	EP 0362526	11-04-90	DFCI		
	26	WO90/08160	07-26-90	Imperial Cancer		
	27	EP 0330191	08-30-89	Gnral Hospital Corp.		
	28	WO 89/08254	08-09-89	La Jolla Cancer		
	29	EP 0359919	03-28-90	ML Technology		

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
B	30	WO 89/06695	07-27-89	Biogen Inc.		
	31					
	32					
	33					
	34					
	35					
	36					
	37					
	38					


Examiner Signature		Date Considered	2/18/04
-----------------------	-------------------------------------------------------------------------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

4

Complete if Known

Application Number	10/033,145
Filing Date	November 5, 2001
First Named Inventor	ROBERTS, Bruce L.
Group Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	GA0201C

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Rg	39	HIESHIMA et al., "A Novel Human CC Chemokine PARC That Is Most Homologous to Macrophage-Inflammatory Protein-1alpha/LD78alpha and Chemotactic for T Lymphocytes, but Not for Monocytes", The Journal of Immunology, 1997, 159:1140-1149	
	40	IMAI et al., "Molecular Cloning of a Novel T Cell-directed CC Chemokine Expressed in Thymus by Signal Sequence Trap Using Epstein-Barr Virus Vector", The Journal of Biological Chemistry, August 1996, 271(35):21514-21521	
	41	GROHMANN et al. "IL-12 Acts Directly on DC to Promote Nuclear Localization of NF-kB and Primes DC for IL-12 Production", Immunity, September 1998, 9:315-323	
	42	VELCULESCU et al., "Serial Analysis of Gene Expression", Science, October 1995, 270:484-487	
	43	WU et al., "RelB Is Essential for the Development of Myeloid-Related CD8alpha- Dendritic Cells but Not of Lymphoid-Related CD8alpha+ Dendritic Cells", Immunity, December 1998, 9:839-847	
	44	YAMANAKA et al., "CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis", International Journal of Molecular Medicine, 1998, 1:213-221	
	45	SCHINDLER et al., "Proteins of transcription factors ISGF-3: One gene encodes the 91- and 84-kDa ISGF-3 proteins that are activated by interferon a", Proceedings of the National Academy of Science, August 1992, 89:7836-7839	
	46	WELTE et al., "Granulocyte-macrophage colony-stimulating factor induces a unique set of STAT factors in murine dendritic cells", European Journal of Immunology, 1997, 27(10):2737-2740	
	47	MASUDA et al., "NFATx, a Novel Member of the Nuclear Factor of Activated T Cells Family That Is Expressed Predominantly in the Thymus", Molecular and Cellular Biology, May 1995, 15(5):2697-2706	
	48	BERKHOUT et al., "Cloning, in Vitro Expression, and Functional Characterization of a Novel Human CC Chemokine of the Monocyte Chemotactic Protein (MCP) Family (MCP-4) That Binds and Signals through the CC Chemokine Receptor 2B", The Journal of Biological Chemistry, June 1997, 272(26):16404-16413	
Rg	49	GODISKA et al., "Human Macrophage-derived Chemokine (MDC), a Novel Chemoattractant for Monocytes, Monocyte-derived Dendritic Cells, and Natural Killer Cells", The Journal of Experimental Medicine, May 1997, 185(9):1595-1604	

Examiner
SignatureDate
Considered

2/18/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	of	4
-------	---	----	---

Complete if Known

Application Number	10/033,145
Filing Date	November 5, 2001
First Named Inventor	ROBERTS, Bruce L.
Group Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	GA0201C

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	2/12/04
-----------------------	-------------------------------------------------------------------------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**